ES2066120T3 - Uso de derivados de bencimidazol como agentes antibacterianos. - Google Patents

Uso de derivados de bencimidazol como agentes antibacterianos.

Info

Publication number
ES2066120T3
ES2066120T3 ES90301256T ES90301256T ES2066120T3 ES 2066120 T3 ES2066120 T3 ES 2066120T3 ES 90301256 T ES90301256 T ES 90301256T ES 90301256 T ES90301256 T ES 90301256T ES 2066120 T3 ES2066120 T3 ES 2066120T3
Authority
ES
Spain
Prior art keywords
antibacterial agents
stands
hydrogen
bencimidazole
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90301256T
Other languages
English (en)
Inventor
Tomoyuki Iwahi
Hiroshi Satoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26370930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2066120(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2066120T3 publication Critical patent/ES2066120T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

EL COMPUESTO REPRESENTADO POR LA FORMULA: [EN DONDE R1 REPRESENTA HIDROGENO, METOXILO O TRIFLUOROMETILO; SIENDO R2 Y R3, IDENTICOS O DIFERENTE UNO DEL OTRO, HIDROGENO O METILO; R4 REPRESENTA UN HIDROCARBURO RESIDUAL OPCIONALMENTE SUBSTITUIDO; Y N DENOTA 0 O 1] O UNA SAL DE EL, MUESTRA EXCELENTE ACTIVIDAD ANTIBACTERIANA, CONTRA EL GENERO "CAMPYLOBACTER", ESPECIALMENTE CONTRA "CAMPYLOBACTER PYLORI", Y SE EMPLEAN PARA PREVENIR O TRATAR ENFERMEDADES INFECCIOSAS OCASIONADAS POR DICHA BACTERIA.
ES90301256T 1989-02-10 1990-02-06 Uso de derivados de bencimidazol como agentes antibacterianos. Expired - Lifetime ES2066120T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3237489 1989-02-10
JP23923389 1989-09-15

Publications (1)

Publication Number Publication Date
ES2066120T3 true ES2066120T3 (es) 1995-03-01

Family

ID=26370930

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90301256T Expired - Lifetime ES2066120T3 (es) 1989-02-10 1990-02-06 Uso de derivados de bencimidazol como agentes antibacterianos.

Country Status (10)

Country Link
US (1) US5013743A (es)
EP (1) EP0382489B1 (es)
AT (1) ATE114114T1 (es)
CA (1) CA2009741C (es)
DE (1) DE69014141T2 (es)
DK (1) DK0382489T3 (es)
ES (1) ES2066120T3 (es)
FI (2) FI100168B (es)
GR (1) GR3014973T3 (es)
NO (1) NO900639L (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338723A (en) * 1989-10-13 1994-08-16 Merck & Co., Inc. Fibrinogen receptor antagonists
AU8445791A (en) * 1990-09-14 1992-04-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Use of pyridylmethylsulphinyl-1h-benzimidazole derivates in the treatment of illnesses caused by helicobacter bacteria
TW209174B (es) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
TW276996B (es) * 1992-04-24 1996-06-01 Astra Ab
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
RU95105442A (ru) * 1992-07-08 1997-02-20 Монсанто Компани (US) Способ лечения язвы желудка у свиней, изделие для лечения язвы желудка у свиней
NZ254237A (en) * 1992-07-28 1995-12-21 Astra Ab Injectable solution of a 2-[(2-pyridyl)methylsulphinyl]-benzimidazole or a salt thereof; an injection kit
DE69302646T2 (de) * 1992-08-21 1996-10-31 Eisai Co Ltd Benzimidazolverbindungen als Antibiotika gegen Campylobacter pylon
WO1994013290A1 (de) * 1992-12-10 1994-06-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von alkylthiopyridinen zur bekämpfung von heliobacter-bakterien
JPH06298611A (ja) * 1993-04-16 1994-10-25 Nippon Chemiphar Co Ltd 抗菌剤
ES2155476T3 (es) * 1993-06-29 2001-05-16 Byk Gulden Lomberg Chem Fab Aril-tio-alquil-tio-piridinas sustituidas.
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
EP1047692B1 (en) 1998-01-14 2004-07-21 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof and methods of treating bacterial and microbial infections with these inhibitors
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
FI104384B (fi) 1998-06-05 2000-01-14 Valmet Corp Laitteisto ja menetelmä viiraveden ja tuoremassan sekoittamiseksi viirakaivon jälkeisessä kanavassa
EP1310252A4 (en) 2000-08-18 2009-06-10 Takeda Pharmaceutical INJECTIONS
CA2445513A1 (en) * 2001-09-18 2003-03-27 Zeria Pharmaceutical Co., Ltd. Benzimidazole derivatives
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1603537A4 (en) * 2003-02-20 2009-11-04 Santarus Inc IMMEDIATE RELEASE OF OMEPRAZOLE ANTACIDAL COMPLEX WITH NEW FORMULATION FOR RAPID AND PROLONGED ELIMINATION OF GASTRIC ACID
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
MXPA06011820A (es) * 2004-04-16 2006-12-15 Santarus Inc Combinacion de inhibidor de bomba de proton, agente regulador del ph y agente procinetico.
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) * 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
BRPI0617987A2 (pt) * 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
EP2003130B1 (en) * 2006-03-10 2011-11-16 aRigen Pharmaceuticals, Inc. Novel pyridine derivative having anti-helicobacter pylori activity
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
CA2654450A1 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US20120041030A1 (en) * 2009-04-09 2012-02-16 Masaichi Yamamoto Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-helicobacter pylori action
JP5309262B2 (ja) 2009-12-02 2013-10-09 アプタリス ファーマ リミテッド フェキソフェナジン・マイクロカプセル及びそれを含む組成物
AR079862A1 (es) * 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS62277322A (ja) * 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤

Also Published As

Publication number Publication date
FI900662A0 (fi) 1990-02-09
GR3014973T3 (en) 1995-05-31
NO900639L (no) 1990-08-13
FI104045B1 (fi) 1999-11-15
EP0382489B1 (en) 1994-11-17
DE69014141T2 (de) 1995-05-24
FI104045B (fi) 1999-11-15
CA2009741A1 (en) 1990-08-10
DK0382489T3 (da) 1995-01-16
CA2009741C (en) 1999-03-23
FI940951A (fi) 1994-02-28
EP0382489A3 (en) 1991-06-12
EP0382489A2 (en) 1990-08-16
FI940951A0 (fi) 1994-02-28
NO900639D0 (no) 1990-02-09
ATE114114T1 (de) 1994-12-15
DE69014141D1 (de) 1994-12-22
FI100168B (fi) 1997-10-15
US5013743A (en) 1991-05-07

Similar Documents

Publication Publication Date Title
ES2066120T3 (es) Uso de derivados de bencimidazol como agentes antibacterianos.
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
PT705833E (pt) Derivado de dc-89
YU11997A (sh) Laktamski derivati i njihove farmaceutske kompozicije
NO900306D0 (no) Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser.
ES2141559T3 (es) Derivados de 2-ciano-1-sulfonamidofenil-1,3-diona y su uso como herbicidas.
PT718293E (pt) Composto ciclodepsipeptidico
ES2115600T3 (es) Derivados de 1-metilcarbapenem y procedimiento para su preparacion.
FI940229A (fi) Trisykliset kondensoituneet heterosykliset yhdisteet, niiden valmistus ja käyttö
NZ217650A (en) Quinoline derivatives and pharmaceutical compositions
FI935800A0 (fi) Antidepressiva och mot Parkisons sjukdom verksamma foereningar
ATE143023T1 (de) Chirale 1,5-diiodo-2-methoxy oder benzyloxy zwischenprodukte
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
FI952420A0 (fi) Glukopyranosidibentsotiofeenit
FI941963A (fi) Pyridiinijohdannaiset, niiden valmistus ja käyttö
DE69017627D1 (de) Isochinolinderivate und ihre Salze als Proteasehemmer.
DE69711506T2 (de) Methylsulfomycin 1, Verfahren zu dessen Herstellung und Verwendung
FI921475A (fi) 1,4-dihydro-4-oxo-3-kinolinderivat som selektivt toxiska antibakteriella aemenn hos daeggdjur.
ES2090056T3 (es) Derivados de pirroloquinolina, su utilizacion como agentes antimicrobianos y procedimientos para su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 382489

Country of ref document: ES